24/7 Wall St. » SNTA

Top Analyst Upgrades & Downgrades (ABMD, MT, BXP, DPZ, DRYS, FET, GPS, BLOX, LYB, OAK, POOL, SNTA, TSLA, URBN, WPI, ZIP)

Administrator — Tue, 22 May 2012 12:31:04 +0000

These are some of the top analyst upgrades, downgrades and initiations seen in Wall Street research calls this Tuesday.

ABIOMED Inc. (NASDAQ: ABMD) Cut to Neutral at Lazard Capital.

ArcelorMittal (NYSE: MT) named Bear of the Day at Zacks.

Boston Properties Inc. (NYSE: BXP) Reiterated Buy with target price of $120 at Argus.

Domino’s Pizza Inc. (NYSE: DPZ) Reiterated Buy with target price of $46 at Argus.

DryShips Inc. (NASDAQ: DRYS) Started as Buy at Global Hunter.

Forum Energy Technologies, Inc (NYSE: FET) Started as Outperform with $28.00 target price at Credit Suisse; Started as Outperform at Howard Weil; Started as Buy at Citigroup.

Gap Inc. (NYSE: GPS) Raised to Buy at Lazard Capital.

Infoblox Inc. (NYSE: BLOX) Started as Buy with $21 target at UBS.

LyondellBasell Industries (NYSE: LYB) Started as Outperform with $60.00 target at Credit Suisse.

Oaktree Capital Group, LLC (NYSE: OAK) Started as Neutral with $45.00 target at Credit Suisse; Started as Buy at Goldman Sachs; Started as Neutral at JPMorgan.

Pool Corporation (NASDAQ: POOL) raised to Bull of the Day at Zacks.

Synta Pharmaceuticals Corp. (NASDAQ: SNTA) Started as Buy at Jefferies.

Tesla Motors, Inc. (NASDAQ: TSLA) Started as Buy at Maxim Group.

Urban Outfitters (NASDAQ: URBN) Maintained as HOLD with $26 target price but lower estimates at Canaccord Genuity.

Watson Pharmaceuticals Inc. (NYSE: WPI) Reiterated Buy with $90 target as “Top Idea Post” at Canaccord Genuity.

Zipcar, Inc. (NASDAQ: ZIP) Started as Overweight at Morgan Stanley.

If you enjoyed the top analyst upgrades and downgrades, you can join our free email newsletter that includes analyst summaries each morning sent right to your inbox. We also cover top issues such as IPOs, special financial exclusives, mergers and more. Sign up in the box below.

JON C. OGG

Filed under: Analyst Calls Tagged: ABMD, BLOX, BXP, DPZ, DRYS, FET, GPS, LYB, MT, OAK, POOL, SNTA, TSLA, URBN, WPI, ZIP

An Early Look at 2012 ASCO Biotech Cancer Stocks (DNDN, LLY, AMGN, ARIA, ARQL, ARRY, AVEO, BVTI, ABPI, BMY, CLDX, CYTR, CYCC, GALE, EXEL, GNBT, GHDX, IMGN, MYGN, NKTR, NLNK, ONXX, OPTR, PCYC, SGEN, SNSS, SNTA)

Administrator — Fri, 18 May 2012 11:47:56 +0000

We are now just about two weeks away from the king of biotech and pharma events in cancer treatments. The 2012 annual meeting of the American Society of Clinical Oncology (ASCO) is set to take place from June 1 to June 5 in Chicago. This has been a make or break event for many cancer treatment and identification efforts. Some of the exhibitors being featured by ASCO are Dendreon, Eli Lilly & Co. (NYSE: LLY), Genentech, Helsinn, Eisai, and Montefiore/Einstein.

24/7 Wall St. has compiled a log of companies which have already signaled in press releases that they will be presenting data or that data will be presented on their behalf at the 2012 ASCO Annual Meeting. We have previewed more than 25 companies so far and that is not even including Big Pharma names. As of May 18, the total abstracts submitted were 5,264 and of those there have been 2,744 which have been accepted for presentation at ASCO. Of those accepted for presentation, some 1,859 are going to be ‘ePublication only’ for viewers. The breakdown for the Abstracts shows that the oral presentation is currently 257 presentations and 2,487 are listed as poster presentation only.

The most presentations accepted (203) so far are focused on Genitourinary Cancer, which covers urinary tract and male genital tract as follows: Prostate cancer; Bladder cancer; Kidney cancer; Testicular cancer; Penile cancer; Nonmalignant tumors of the urinary tract and male reproductive system; and Von Hippel Lindau disease. As of today, the fewest accepted presentations (93) cover Pediatric oncology.

Amgen Inc. (NASDAQ: AMGN), the largest independent biotech that there is, recently showed updated results from a Phase 2 study showing that treatment with blinatumomab helped achieve a high-rate of complete response in 72% of adult patients with relapsed or refractory B-precursor acute lymphoblastic leukemia treated in the study. This blinatumomab is the first of a new class of agents called bi-specific T cell engagers antibodies, which are designed to harness the body’s cell-destroying T cells to kill cancer cells. Blinatumomab targets cells expressing CD19, a protein found on the surface of B-cell derived leukemias and lymphomas, such as ALL. Full results of the study will be presented during an oral abstract session on June 4 at the ASCO Annual Meeting.

ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) recently sold off but will will have updated clinical data from the pivotal PACE trial of ponatinib, its investigational pan-BCR-ABL inhibitor in patients with chronic myeloid leukemia (CML) on June 4. The company said that the data will form the basis of its regulatory filings for marketing approval of Ponatinib for patients with chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblasatic leukemia.

ArQule, Inc. (NASDAQ: ARQL) and Daiichi Sankyo, Co., Ltd. (Japan) will have an oral presentation at the ASCO Annual Meeting featuring Phase 2 trial data with tivantinib as a single agent investigational second-line treatment in hepatocellular carcinoma. ArQule announced that this randomized, double-blind study met its primary endpoint in January and will now present the full results from this trial, including positive data in the pre-defined c-MET high population. Additional clinical data with tivantinib will be featured in two poster discussions and two general poster sessions.

Array BioPharma Inc. (NASDAQ: ARRY) has recently risen on its lung cancer and melanoma results. The company has three oral presentations at the annual meeting after having already presented Phase 1 data on MEK162 in 28 patients with biliary tract cancer at the ASCO Gastrointestinal Cancers Symposium in January 2012 showing that it was well tolerated and showed evidence of clinical efficacy in this patient population, including a complete response and a partial response. Stable disease was observed in 12 patients. The company has licensed selumetinib to AstraZeneca (NYSE: AZN) and licensed MEK162 to Novartis (NYSE: NVS).

Filed under: Biotech, Calendar, Cult Stock, Drug companies, Editor's Picks, Healthcare, Medical Tagged: ABPI, AMGN, ARIA, ARQL, ARRY, AVEO, BMY, BVTI, CLDX, CYCC, CYTR, DNDN, EXEL, GALE, GHDX, GNBT, IMGN, LLY, MYGN, NKTR, NLNK, ONXX, OPTR, PCYC, SGEN, SNSS, SNTA

Full 2009 ASCO Cancer & Oncology Primer (ABII, AEZS, ALTH, AMGN, APPA, ARQL, BMY, CLDX, CELG, CTIC, CGRB, LLY, EXEL, GHDX, GSK, IMGN, MEDX, MDVN, MITI, OGXI, OSIP, PPHM, PFE, ROSG, SNTA, TRBN, ZIOP, ZGEN)

247wallst — Wed, 27 May 2009 18:34:32 +0000

We have compiled an updated lengthy 2009 American Society of Clinical Oncology, or ASCO, document showing many company cancer data presentations slated to start this weekend. This is broken down in drug and biotech companies with share values, ranges, and recent developments for the following drug and biotech companies: Abraxis BioScience, Inc. (NASDAQ:ABII), AEterna Zentaris Inc. (NASDAQ: AEZS), Allos Therapeutics, Inc. (NASDAQ: ALTH), Amgen Inc. (NASDAQ: AMGN), A.P. Pharma, Inc. (Nasdaq: APPA), Arqule Inc. (NASDAQ: ARQL), Bristol-Myers Squibb (NYSE: BMY), Celldex Therapeutics (NASDAQ: CLDX), Celgene Corporation (NASDAQ: CELG), Cell Therapeutics (NASDAQ: CTIC), Cougar Biotechnology, Inc. (NASDAQ: CGRB), Eli Lilly and Company (NYSE: LLY), Exelixis (NASDAQ: EXEL), Genomic Health, Inc. (NASDAQ: GHDX), GlaxoSmithKline (NYSE: GSK) , Immunogen (NASDAQ: IMGN), Medarex (NASDAQ: MEDX), Medivation, Inc. (NASDAQ: MDVN), Micromet, Inc. (NASDAQ: MITI), OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI), OSI Pharmaceuticals (NASDAQ: OSIP), Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM), Pfizer Inc. (NYSE: PFE), Rosetta Genomics (NASDAQ:ROSG), Synta Pharmaceuticals (NASDAQ: SNTA), Trubion Pharmaceuticals, Inc. (Nasdaq: TRBN), ZIOPHARM Oncology (NASDAQ: ZIOP), and ZymoGenetics, Inc. (NASDAQ: ZGEN).

The full presentation can be seen at BioHealthInvestor.com.

JON C. OGG
May 27, 2009

Posted in Biotech, Drug companies, FDA, Medical, Pharmaceuticals Tagged: ABII, AEZS, ALTH, AMGN, APPA, ARQL, BMY, CELG, CGRB, CLDX, CTIC, EXEL, GHDX, GSK, IMGN, LLY, MDVN, MEDX, MITI, OGXI, OSIP, PFE, PPHM, ROSG, SNTA, TRBN, ZGEN, ZIOP

Previewing 2009 ASCO Abstracts (ABII, ALTH, ARQL, CLDX, CTIC, CGRB, LLY, EXEL, GHDX, GSK, IMGN, MEDX, MDVN, OGXI, OSIP, PPHM, PFE, SNTA, ZIOP)

247wallst — Thu, 14 May 2009 21:56:52 +0000

We are just about to get the first round of abstracts from companies presenting data at this year’s American Society of Clinical Oncology meeting for 2009. At BioHealthInvestor.com we compiled a brief summary for companies such as Abraxis BioScience, Inc. (NASDAQ:ABII), Allos Therapeutics, Inc. (NASDAQ: ALTH), Arqule Inc. (NASDAQ: ARQL), Celldex Therapeutics (NASDAQ: CLDX), Cell Therapeutics (NASDAQ: CTIC), Cougar Biotechnology, Inc. (NASDAQ: CGRB), Eli Lilly and Company (NYSE: LLY), Exelixis (NASDAQ: EXEL), Genomic Health, Inc. (NASDAQ: GHDX), GlaxoSmithKline (NYSE: GSK) , Immunogen (NASDAQ: IMGN), Medarex (NASDAQ: MEDX), Medivation, Inc. (NASDAQ: MDVN), OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI), OSI Pharmaceuticals (NASDAQ: OSIP), Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM), Pfizer Inc. (NYSE: PFE), Synta Pharmaceuticals (NASDAQ: SNTA), and ZIOPHARM Oncology (NASDAQ: ZIOP).

You can see that full pre-report here at BiohealthInvestor.com. As always be advised that there may be new sets of data released between now and the actual meeting from May 29 to June 2, 2009 in Orlando, Florida.

Posted in Biotech, Drug companies, Medical, Pharmaceuticals Tagged: ABII, ALTH, ARQL, CGRB, CLDX, CTIC, EXEL, GHDX, GSK, IMGN, LLY, MDVN, MEDX, OGXI, OSIP, PFE, PPHM, SNTA, ZIOP

The 52-Week Low Club (TSCM)(EBAY)(GE)(SNTA)(ABK)(C)

247wallst — Fri, 27 Feb 2009 20:55:43 +0000

Citigroup (C) Government will take a 36% share. Drops to $1.42 from 52-week high of $27.35.

AMBAC Inc (ABK) Market hates it earnings. Drop to $.56 from 52-week high of $12.37.

Synta Pharmaceuticals (SNTA) Drug trial suspended. Multiple broker downgrades. The daily double. Off to $1.31 from 52-week high of $10.30.

GE (GE) Cuts dividend. Falls to $8.40 from 52-week high of $38.52.

Ebay (EBAY) Concerns recession will hurt e-commerce. Sells down to $10.50 from 52-week high of $33.47.

TheStreet.com (TSCM) Financial advertising falling apart. Down to $1.87 from 52-week high of $9.49.

Douglas A. McIntyre

Posted in HI/LOW Tagged: ABK, C, EBAY, GE, SNTA, TSCM

Top Pre-Market Analyst Downgrades (ADBE, ADSK, LLNW, NIHD, ORLY, QSFT, SLM, SNTA, USM)

247wallst — Fri, 27 Feb 2009 13:49:20 +0000

These are the top pre-market analyst downgrades and negative research calls we have seen this Friday morning:

Adobe (ADBE) Cut to Market Perform at Wachovia.
Autodesk (ADSK) Cut to Hold at KeyBanc.
Limelight Networks (LLNW) Cut to Hold at Jefferies.
NII Holdings (NIHD) Cut to Neutral at Piper Jaffray.
O’Reilly Autoparts (ORLY) Cut to Hold at Deutsche Bank.
Quest Software (QSFT) Cut to Market Weight at Thomas Weisel.
SLM (SLM) Cut to Equal Weight at Barclays.
Synta Pharmaceuticals (SNTA) downgraded at Lazard, Roth Capital, and Wachovia.
US Cellular (USM) Cut to Underperform at Baird.

JON C. OGG

Posted in Analyst Calls Tagged: ADBE, ADSK, LLNW, NIHD, ORLY, QSFT, SLM, SNTA, USM

Pre-Market Stock News (January 28, 2008)

247wallst — Mon, 28 Jan 2008 07:54:46 +0000

Alliance Data Systems (ADS) was informed by Blackstone that conditions likely won’t be satisfied to complete the merger; stock trading down close to 40%.
American Express (AXP) reports earnings today with estimates at $0.71 EPS.
Biogen Idec (BIIB) said that Carl Icahn has given notice that he wants to nominate 3 directors to the board.
Black & Decker (BDK) $1.06 EPS vs. $1.03 estimate; lowered guidance for 2008 to $5.40 to 5.90 vs. $6.10+ estimates.
Bluelinx (BXC) now sees wider losses than expected.
Corning (GLW) $0.40 EPS vs. $0.39 estimate; Revenue $1.58B vs. $1.55B est.
eBay (EBAY) announced that PayPal has agreed to acquire Fraud Sciences Ltd. in Israeli for roughly $169 million.
FPL Group (FPL) $0.71 EPS vs. $0.67 estimates.
Halliburton (HAL) $0.74 EPS vs. $0.69 estimates.
Matria Healthcare (MATR) is being acquired by Inverness Medical (IMA) for $39.00 per share, with a breakdown of $6.50 per share in cash and $32.50 per share in convertible preferred stock.
McDonalds (MCD) set to report earnings, estimate $0.71.
Napster (NAPS) announced the launch of the Napster Mobile music service with Ericsson phones at Telecom Italia through its mobile brand TIM.
Sallie Mae (SLM) received commitments for $31 Billion from a consortium of banks led by Bank of America, JPMorgan Chase, Barclays Capital, Deutsche Bank, Credit Suisse, and The Royal Bank of Scotland, and from UBS; new financing will replace the $30 billion interim financing put in place; will drop suit related to past failed merger.
Sears Holdings (SHLD) Aylwin Lewis is stepping down as CEO of Sears.
Stanley Works (SWK) $1.11 EPS vs. $1.10 estimate; reaffirmed 2008 EPS at $4.20 to $4.40 versus $4.37 estimate.
Superior Offshore (DEEP) announced E. Donald Terry will be Interim President/CEO effectively immediately.
Synta (SNTA) and GlaxoSmithKline (GSK) announced elesclomol for metastatic melanoma was granted orphan drug designation by FDA; SNTA trading up 17%.
Ultralife Batteries (ULBI) received $4.4 million in military battery orders from the U.S. Defense Department.
Verizon (VZ) $0.62 EPS vs $0.62 estimate; added 2 million total net wireless customers; now has over 1 million FiOS TV customers.

Jon C. Ogg
January 28, 2008